Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Sarepta Therapeutics stock in Canada | $73.05
Own Sarepta Therapeutics shares in just a few minutes.
Sarepta Therapeutics (SRPT) is a leading biotechnology business based in the US. It opened the day at $73.01 after a previous close of $72.94. During the day the price has varied from a low of $71.818 to a high of $73.18. The latest price was $73.05 (25 minute delay). Sarepta Therapeutics is listed on the NASDAQ and employs 866 staff. All prices are listed in US Dollars.
How to buy Sarepta Therapeutics stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: SRPT in this case.
- Research Sarepta Therapeutics stocks. The platform should provide the latest information available.
- Buy your Sarepta Therapeutics stocks. It's that simple.
What's in this guide?
- Can I buy shares in Sarepta Therapeutics?
- Has coronavirus impacted Sarepta Therapeutics shares?
- Sarepta Therapeutics shares summary
- Compare share dealing platforms
- Is Sarepta Therapeutics stock a buy or sell?
- Sarepta Therapeutics performance over time
- Can I short Sarepta Therapeutics shares?
- Are Sarepta Therapeutics shares over-valued?
- Sarepta Therapeutics's financials
- How volatile are Sarepta Therapeutics shares?
- Does Sarepta Therapeutics pay a dividend?
- Have Sarepta Therapeutics shares ever split?
- Other common questions
How has Coronavirus impacted Sarepta Therapeutics's stock price?
Since the stock market crash in March caused by coronavirus, Sarepta Therapeutics's stock price has had significant negative movement.
Its last market close was $75.65, which is 38.98% down on its pre-crash value of $123.98 and 3.19% down on the lowest point reached during the March crash when the stocks fell as low as $78.06.
If you had bought $1,000 worth of Sarepta Therapeutics stocks at the start of February 2020, those stocks would have been worth $774.92 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $655.89.
Sarepta Therapeutics stock priceUse our graph to track the performance of SRPT stocks over time.
Sarepta Therapeutics stocks at a glance
|52-week range||$65.3 - $181.83|
|50-day moving average||$75.4143|
|200-day moving average||$79.688|
|Wall St. target price||$125.82|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-8.135|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Sarepta Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Sarepta Therapeutics price performance over time
|1 month (2021-07-02)||-2.91%|
|3 months (2021-05-03)||-5.27%|
Is Sarepta Therapeutics under- or over-valued?
Valuing Sarepta Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sarepta Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sarepta Therapeutics's PEG ratio
Sarepta Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 159.25. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sarepta Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
Sarepta Therapeutics financials
|Revenue TTM||USD$573.4 million|
|Gross profit TTM||USD$-245,526,000|
|Return on assets TTM||-12.86%|
|Return on equity TTM||-83.78%|
|Market capitalisation||USD$5.4 billion|
TTM: trailing 12 months
How to short and sell Sarepta Therapeutics stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "SRPT.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 6.5 million Sarepta Therapeutics stocks held short by investors – that's known as Sarepta Therapeutics's "short interest". This figure is 0.9% up from 6.4 million last month.
There are a few different ways that this level of interest in shorting Sarepta Therapeutics stocks can be evaluated.
Sarepta Therapeutics's "short interest ratio" (SIR)
Sarepta Therapeutics's "short interest ratio" (SIR) is the quantity of Sarepta Therapeutics stocks currently shorted divided by the average quantity of Sarepta Therapeutics stocks traded daily (recently around 800737.85450062). Sarepta Therapeutics's SIR currently stands at 8.11. In other words for every 100,000 Sarepta Therapeutics stocks traded daily on the market, roughly 8110 stocks are currently held short.
However Sarepta Therapeutics's short interest can also be evaluated against the total number of Sarepta Therapeutics stocks, or, against the total number of tradable Sarepta Therapeutics stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sarepta Therapeutics's short interest could be expressed as 0.08% of the outstanding stocks (for every 100,000 Sarepta Therapeutics stocks in existence, roughly 80 stocks are currently held short) or 0.0854% of the tradable stocks (for every 100,000 tradable Sarepta Therapeutics stocks, roughly 85 stocks are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Sarepta Therapeutics.
Find out more about how you can short Sarepta Therapeutics stock.
Sarepta Therapeutics stock dividends
We're not expecting Sarepta Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Have Sarepta Therapeutics stocks ever split?
Sarepta Therapeutics stocks were split on a 1:6 basis on 12 July 2012. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sarepta Therapeutics stocks – just the quantity. However, indirectly, the new 500% higher stock price could have impacted the market appetite for Sarepta Therapeutics stocks which in turn could have impacted Sarepta Therapeutics's stock price.
Sarepta Therapeutics stock price volatility
Over the last 12 months, Sarepta Therapeutics's stocks have ranged in value from as little as $65.3 up to $181.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sarepta Therapeutics's is 1.4358. This would suggest that Sarepta Therapeutics's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Sarepta Therapeutics overview
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Stocks similar to Sarepta Therapeutics
Sarepta Therapeutics in the news
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: Should You Buy?
Frequently asked questions
More guides on Finder
How to buy Wheels Up (UP) stock in Canada when it goes public
Everything we know about the Wheels Up IPO, plus information on how to buy in.
How to invest $1 million
Here are the top 5 ways you should invest $1 million.
How to buy Brookfield Asset Management Reinsurance Partners Ltd (BAMR) stock in Canada when it goes public
Everything we know about the Brookfield Asset Management Reinsurance Partners Ltd IPO, plus information on how to buy in.
How to buy Traeger (COOK) stock in Canada
Everything we know about the Traeger IPO, plus information on how to buy in.
How to buy Teads (TEAD) stock in Canada when it goes public
Everything we know about the Teads IPO, plus information on how to buy in.
How to buy Snap One Holdings Corp (SNPO) stock in Canada
Everything we know about the Snap One Holdings Corp IPO, plus information on how to buy in.
How to buy Riskified (RSKD) stock in Canada
Everything we know about the Riskified IPO, plus information on how to buy in.
How to buy Preston Hollow Community Capital (PHCC) stock in Canada when it goes public
Everything we know about the Preston Hollow Community Capital IPO, plus information on how to buy in.
How to buy PowerSchool Holdings (PWSC) stock in Canada
Everything we know about the PowerSchool Holdings IPO, plus information on how to buy in.
How to buy MeridianLink (MLNK) stock in Canada
Everything we know about the MeridianLink IPO, plus information on how to buy in.
Ask an Expert
You must be logged in to post a comment.